Marc Dall'Era, M.D.

Marc A. Dall'Era, M.D.



Urologic Oncology


Robotic Surgery

Surgery - Robotic


Urologic Surgery


  • Vice Chair, Department of Urologic Surgery
  • Professor


To see if Marc A. Dall'Era is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Lawrence J. Ellison Ambulatory Care Center

4860 Y St., Suite 2200
Sacramento, CA 95817
Driving Directions

Primary Phone:

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:

Additional Phone Numbers

Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Clinical Interests

Dr. Dall’Era specializes in the management of malignant disease of the urinary tract. 

The specialty care Dr. Dall’Era offers includes:

  • Multi-disciplinary and comprehensive care of patients with urologic malignancy
  • Active surveillance for low risk prostate cancer
  • Multi-parametric MRI/US fusion targeted prostate biopsy
  • Blue Light Fluorescent cystoscopy for bladder cancer with Cysview
  • Minimally invasive and robotic surgery of the kidney and prostate including prostatectomy, partial nephrectomy, pyeloplasty/ureteral reconstruction
  • Radical cystectomy and neobladder creation
  • Advanced genomics testing of urologic cancers


Research/Academic Interests

Dr. Dall'Era's research interests include active surveillance for prostate cancer including utilization of mp-MRI and biomarker discovery and validation. He is also involved in translational research for urothelial cancer diagnosis and management including advanced genomics analysis of bladder tumors.



Center/Program Affiliation

UC Davis Comprehensive Cancer Center


M.D., UC Davis, Davis CA 2000

B.S., UC Davis, Davis CA 1995

Internship: General Surgery, University of Washington, Seattle WA 2000-2001


Urology, University of Washington, Seattle WA 2001-2005


Oncology, UC San Francisco, San Francisco CA 2006-2008

Board Certifications

American Board of Urology,

Professional Memberships

American Association of Clinical Urologists

American Urological Association

Data and Safety Monitoring Board for the Prostate, Board Member

Genitourinary (GU) Cancers Symposium News Planning

Society of Urologic Oncology (SUO), Committee Member - Prostate Cancer Committee

Society of Urologic Oncology (SUO), Spring Scientific Program Co-Chair

Western Section American Urological Association, Board of Directors

Select Recent Publications

To view a detailed list of  Dr. Dall'Era's publications, please click here.

Dall'Era, MA, Klotz, L. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer and Prostatic Diseases. 2017;20(1):1-6.

Yap, SA, Yuh, LM, Evans, CP, Dall'Era, MA, Wagenaar, RM, Cress, R, Lara, PN. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World Journal of Urology. 2017;35(2):277-283.

Pugashetti, N, Chandrasekar,T, Lurvey, R, Durbin-Johnson, B, Dall'Era, M, de Vere White, R, Evans, C, Yap, S. Perioperative Outcomes Following Neoadjuvant Chemotherapy and Radical Cystectomy-Is There Room for Improvement? Urology Practice Journal. 2016;3:364-370.

Pan, A, Zhang, H, Li, Y, Lin, T, Wang, F, Lee, J, Cheng, M, Dall'Era, M, Li, T, de Vere White, R, Pan, C, Lam, K. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016;27(42): 1-9.

Chandrasekar, T, Pugashetti, N, Durbin-Johnson, B, Dall'Era, MA, Evans, CP, de Vere White, RW, Yap, SA. Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Bladder cancer (Amsterdam, Netherlands). 2016;2(4): 441-448.

Chow, H, Ghosh, PM, de Vere White, R, Evans, CP, Dall'Era, MA, Yap, SA, Li, Y, Beckett, LA, Lara, PN, Pan, CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016;122(12):1897-904.

Marc A. Dall'Era, Benjamin J. Davies. Clinical Case Discussion: Intermediate-Risk Prostate Cancer: The Case for Active Surveillance. European Urology Focus. 2015;1(2):208-209.

Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A retrospective Chart Review Analysis. Urology Practice. 2015;2:343-348.

Yuh L, Dall’Era MA, Penson DF, Evan CP. Active Surveillance for Prostate Cancer Under the Patient Protection and Affordable Act. Urology Practice. 2015;2(4):154-159.

Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall’Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Canadian Urological Association Journal. 2015;9(3-4):E204-207.